News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

France Biotech Presents the Results of its Tenth Annual "Life Science Panorama 2011" Survey, Conducted in Partnership With Ernst & Young LLP


5/23/2012 11:13:30 AM

Paris, Tuesday, 23 May 2012 - France Biotech, the French association of life science companies, in partnership with Ernst & Young, published for the 10th year running the 'Life Science Panorama', describing the industry's main trends for 2010/2011 in France and worldwide. This time, almost 200 French companies took part in the survey. The panorama highlights the maturity threshold attained by the life science industry, equivalent to that of the pharmaceutical industry thanks to a wide variety of highly sought-after products. It also focuses on the first acquisitions of foreign companies by French companies and the first takeovers of listed French companies. In this time of crisis, France has clearly demonstrated the momentum of this sector, but will it run the risk of decline in the years to come due to reduced financing?

'In spite of the difficult period we are going through, our sector is proving its vitality. Its turnover is continuing to increase significantly and it is entering into partnerships with high potential. Will venture capital, which remains THE source of financing for the expansion of our industry, be able to meet the needs of the sector, taking into account the unprecedented drop in financing observed in 2011? The capital strength of our companies will be the fundamental means of support for growth, so that we may continue to take on staff, innovate and post solid performances. France Biotech has warned the Government about the impact of the innovation grant reforms, which have blocked the path of many of our fast-developing companies, and may continue to do so. Each SME in our sector is a large company in the making. France Biotech will continue battling to get the Government to review its standpoint on the recent reforms and will remain vigilant as regards future reforms,', stated André Choulika, Chairman of France Biotech.

France ranked 2nd in the world (source: OECD) in terms of number of life science companies

There are 1,359 life science companies throughout France. They are mainly located in the Ile de France region (33% as in 2010), the Rhône-Alpes region (15% as against 16.6% in 2010) and the PACA (Provence-Alpes-Côte d'Azur) region (8.2% as against 10.5% in 2010). It should be noted that 6% of these companies are in the Midi-Pyrénées region and 6.6% (4.9% in 2010) in the Loire region, a trend boosted by the centre of competitive excellence. AND 48.5% of the French companies are from the academic sector.

Biotech companies, real growth opportunities for the pharmaceutical sector, with partnerships still on the up Over the past few years, biotechnology companies have become the main potential for growth for the pharmaceutical industry, now the largest client of innovative companies (33%), along with public research laboratories.

85 partnerships were entered into in 2011. Biotechnology companies often stem from an academic discovery and then remain closely affiliated with their laboratory of origin. The percentage of partnerships stemming from academic research rose from 49% in 2010 to 52% in 2010, showing an increase in this field.

A sector struggling to finance itself and attain mid-cap status

The financing of French companies in the sector1 (via venture capital, IPOs or refinancing on the financial markets) dropped sharply between 2010 and 2011, falling by 40% from €460 million to €277 million. This trend could also be observed in the biotech sector in Europe, where financing fell by 36%.

In parallel, the companies questioned continue to overwhelmingly favor the various tools made available to the public authorities (Oséo - French state innovation agency, C.I.R. - tax rebates for research), whilst underlining, however, the extremely negative impact of the reform of the Young Innovative Company status.

"As financial resources continue to dry up, companies in the sector will have to develop more rapidly. Therefore, concentration phenomena could increase, or we may be faced with the development of the 'open innovation' phenomenon,'" concluded Franck Sebag, a partner at Ernst & Young.

1 This year, the study analyzed biotechnology companies and companies in the medtech sector

About France Biotech

France Biotech (www.france-biotech.org) is the French association of life science businesses and their partners. Its mission is to help the French life science industry to achieve a leading position in Europe. France Biotech is a driving force for change; it lobbies public authorities, economic organizations, academic research, the media and, particularly, the investor community in order to encourage the emergence of biotechnology as a top-priority, hi-tech industry and to improve the economic, legal, regulatory and managerial environment of these businesses. France Biotech currently has 150 members. The association's corporate members account for the vast majority of the investments, employees and innovative products in France's life science sector.

About Ernst & Young

Ernst & Young is a global leader in assurance, tax, transaction and advisory services. Worldwide, our 152,000 people are united by our shared values and an unwavering commitment to quality. We make a difference by helping our people, our clients and our wider communities achieve their potential.

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit www.ey.com.

Press Contacts:

France Biotech

Haude Costa (Secretary General)

haude.costa@france-biotech.org

Tel.: +33 1 56 58 10 70 / +33 6 84 25 88 27

Alize Public Relations

Caroline Carmagnol

caroline@alizerp.com

Tel.: +33 6 64 18 99 59/01 42 68 86 43

Ernst & Young

Annabelle Rousseau / Press Contact

Office: +33 (0)1 55 61 80 33

Cell: +33 (0)6 89 88 37 53

annabelle.rousseau@fr.ey.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES